IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-α
| Autor: | D. Scott Bowden, Paul V. Desmond, Ferry Rusli, Robert Chen, Tin Nguyen, Anouk Dev, David Iser, Jane V. Tehan, Stephen Pianko, Sally Bell, R. Hammond, Dilip Ratnam, Alexander J. Thompson, S. Bonanzinga, Kumar Visvanathan, Neel M Heerasing, Jacinta A Holmes, William Sievert |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Hepatitis
Hepatitis B virus medicine.medical_specialty Hepatology business.industry Gastroenterology virus diseases Lamivudine Hepatitis B medicine.disease medicine.disease_cause digestive system diseases Liver disease HBeAg Pegylated interferon Internal medicine Genotype Immunology medicine business medicine.drug |
| Zdroj: | Journal of Gastroenterology and Hepatology. 28:861-866 |
| ISSN: | 0815-9319 |
| DOI: | 10.1111/jgh.12110 |
| Popis: | Background and Aim IL28B genotype predicts response to pegylated interferon (peg-IFN)-based therapy in chronic hepatitis C. However, the utility of IL28B genotyping in chronic hepatitis B (CHB) cohorts treated with peg-IFN is unclear. It was investigated whether IL28B genotype is associated with peg-IFN treatment outcomes in a predominantly Asian CHB cohort. Methods This was a retrospective analysis of CHB patients treated with 48 weeks of peg-IFN monotherapy. IL28B genotype (rs12979860) was determined (TaqMan allelic discrimination kit). Baseline hepatitis B virus (HBV)-DNA, alanine aminotransferase, and liver histology were available. The primary end-points were HBV e antigen (HBeAg) seroconversion with HBV-DNA |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text